Allogeneic Cell Therapies Summit Presentation
Streamline Cell & Gene Therapy Development with High Quality Cellular Materials, In-House Apheresis Capabilities & Multi-Omics Analytical Services
November 4, 2020
Never Miss an Update
Sign up and receive Discovery updates, blogs, and market news directly to your inbox.
Subscribe NowPresented at ACTS
October 26, 2020
The quality of initial cellular raw material has a large impact on cell and gene therapy manufacturing and final product performance. This presentation will discuss Discovery Life Sciences’ capability to provide high-quality cellular material for cell and gene therapy manufacturing by integrating in-house apheresis collections across 2,800+ recallable donors with immunophenotyping, high resolution NGS HLA typing, flow cytometry, immune cell isolation and culture services.
Ask Your Questions
Have a question related to this presentation? Submit this form and we will get you answers.
To propel your projects with The Power of Discovery.™
Contact Us Today
Let us know about your project!
